At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 17, 2026 at 08:00 ET
Cogent Biosciences presented preclinical data at AACR 2026 for two pipeline candidates: CGT1263, a pan-KRAS(ON) inhibitor with potential differentiation in skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergy with HER2 ADCs in resistant patients. IND submission for CGT1263 is expected later this year, while Phase 1 trials for CGT4255 are ongoing.
- Presented preclinical data for CGT1263, a pan-KRAS(ON) inhibitor with >500x selectivity for mutant KRAS over HRAS/NRAS, potentially reducing skin toxicity seen with multi-RAS inhibitors.
- CGT1263 shows sustained pERK inhibition and robust antitumor activity in preclinical models, with limited skin suppression suggesting a wider therapeutic window.
- Presented data for CGT4255, a brain-penetrant ErbB2 inhibitor with >100-fold selectivity over EGFR, active against key HER2 mutations and showing synergistic effects when combined with HER2 ADCs like T-DXd.
- IND submission for CGT1263 expected later in 2026; Phase 1 trial for CGT4255 is already ongoing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access